Miércoles, 30 de Mayo de 2012

Sesión de control

Rajoy dice que con la crisis es muy difícil aprobar enmiendas a los PGE

Precio	Variación	Volumen (títulos)	Volumen ($)	Hora
32,640$	+6,42% +1,970$	35.843.367	988.872.162,22	22:00:24

Noticias Medio ambiente

Merck profit beats forecast, revenue lags

27/04

(Reuters) - Merck & Co reported quarterly earnings slightly above Wall Street forecasts, helped by cost controls, but revenue trailed expectations on generic competition and reduced revenue from alliances with other drugmakers.

Merck to pay $950 million to settle U.S. Vioxx charge

23/11

By Anna Yukhananov

Merck to pay $950 million to settle U.S. Vioxx charge

22/11

By Anna Yukhananov

Merck to pay about $950 million to settle U.S. Vioxx charge

22/11

(Reuters) - Merck & Co will pay roughly $950 million to settle criminal and civil charges that it promoted the painkiller Vioxx for an unapproved use, the U.S. Justice Department said on Tuesday.

Merck to pay nearly $1 billion to settle U.S. charges

22/11

(Reuters) - Merck & Co will pay roughly $950 million to settle criminal and civil charges that it promoted the painkiller drug Vioxx for an unapproved use, the U.S. Justice Department said on Tuesday.

Merck pares 2010 forecast, despite beat in quarter

30/07

By Ransdell Pierson

Merck pares 2010 forecast, despite beat in quarter

30/07

By Ransdell Pierson

Merck profit beats Wall Street view

30/07

NEW YORK (Reuters) - Merck & Co reported higher-than-expected second-quarter earnings on Friday, helped by strong sales of its treatments for diabetes, arthritis and HIV.